Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,303
Out of 5,090 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $36.23 | +15.93% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $157.21 | +138.53% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $81.40 | +41.28% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $80.73 | +13.96% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $13.27 | -9.57% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $9.60 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $70.79 | +27.14% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $263.28 | +2.55% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $108.51 | -37.33% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $11.26 | +299.64% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $120.50 | +128.22% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $25.38 | +45.78% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $65.49 | -8.38% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $97.52 | -64.11% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $304.49 | -73.40% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $36.23
Upside: +15.93%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $157.21
Upside: +138.53%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $81.40
Upside: +41.28%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $80.73
Upside: +13.96%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $13.27
Upside: -9.57%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $9.60
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $70.79
Upside: +27.14%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $263.28
Upside: +2.55%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $108.51
Upside: -37.33%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $11.26
Upside: +299.64%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $120.50
Upside: +128.22%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $25.38
Upside: +45.78%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $65.49
Upside: -8.38%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $97.52
Upside: -64.11%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $304.49
Upside: -73.40%